시장보고서

상품코드

1584135

신경내분비종양 치료 시장 : 치료 유형별, 약제 클래스별, 종양 유형별, 최종사용자별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2024-2032년)

Neuroendocrine Tumor Treatment Market, By Therapy Type, By Drug Class, By Tumor Type, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

발행일: 2024년 11월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 316 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

리포트 하이라이트

신경내분비종양(NET) 치료 시장 규모는 2023년에 25억 1,021만 달러에 달하며, 2024-2032년 CAGR 9.10%로 확대

신경내분비종양 치료 시장 - 시장 역학

임상시험 수의 증가가 신경내분비종양 치료 시장의 혁신을 가속

임상시험 증가는 신경 내분비 종양 치료 시장의 혁신을 크게 가속화하고 있으며, 이는 표적 치료법 개발에 점점 더 많은 초점을 맞추고 있음을 반영합니다. 예를 들어 2021년미국 국립 보건원(NIH)은 NET에 특화된 350개 이상의 활발한 임상시험을보고하여 새로운 치료 방법을 모색해야 할 시급성을 강조했습니다. 노바티스와 입센과 같은 제약회사들은 소마토스타틴 유사체 및 펩티드 수용체 방사성 핵종 요법(PRRT)과 같은 새로운 약물을 평가하기 위한 임상 연구에 많은 투자를 하고 있습니다. 또한 유럽신경내분비종양학회(European Neuroendocrine Tumor Society, ENETS)와 같은 구상은 공동연구를 촉진하고 치료 프로토콜을 빠르게 발전시키는 데 도움을 주고 있습니다. 그 결과, 신경내분비종양 진단을 받은 환자들의 예후와 삶의 질을 개선할 수 있는 유망한 새로운 치료법이 개발될 것으로 기대됩니다.

신경내분비종양 치료제 시장 - 주요 인사이트

당사의 리서치 애널리스트가 공유한 분석에 따르면 세계 시장은 예측 기간(2024-2032년) 동안 매년 약 9.10%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상됩니다.

치료 유형별로는 소마토스타틴 유사체 요법이 22023년 가장 높은 시장 점유율을 차지했습니다.

약물 유형별로는 2023년 소마토스타틴 유사체가 주요 유형으로 부상할 것으로 예상됩니다.

종양 유형별로는 2023년 소화관 췌장 신경내분비종양(GEP-NET)이 주요 유형이 될 것으로 보입니다.

지역별로는 북미가 2023년 주요 수입원이었습니다.

신경내분비종양치료제 시장 - 세분화 분석 :

세계 신경내분비 종양 치료 시장은 치료 유형, 약물 유형, 종양 유형, 최종사용자 및 지역별로 분류됩니다.

시장은 치료 유형에 따라 소마토스타틴 유사체 요법, 펩티드 수용체 방사성 핵종 요법(PRRT), 표적 요법, 화학요법 등 4가지 범주로 나뉩니다. 소마토스타틴 유사체 요법은 증상 조절에 대한 효과가 입증되어 1위를 차지합니다. 그 뒤를 이어 펩티드 수용체 방사성 핵종 치료(PRRT)가 표적 치료의 선두를 달리고 있습니다. 표적치료와 화학요법도 우선순위는 낮지만 중요한 치료법입니다.

약물 유형에 따라 시장은 소마토스타틴 유사체, 티로신 키나아제 억제제, mTOR 억제제, 알킬화제 등 네 가지로 분류됩니다. 소마토스타틴 유사체는 증상 및 종양 성장 관리에 효과적이기 때문에 가장 우선순위가 높으며, mTOR 억제제와 알킬화제 역시 중요하지만 우선순위는 낮습니다.

신경내분비종양치료제 시장 - 지역적 인사이트

신경내분비종양(NET) 치료 시장은 지역별로 유병률, 치료 옵션, 연구 활동에서 큰 차이를 보이고 있습니다. 북미는 첨단 의료 인프라와 종양학 연구에 대한 막대한 투자로 인해 주요 지역으로 부상하고 있으며, 미국암협회에 따르면 미국에서는 매년 약 12,000건의 새로운 NET 사례가 보고되고 있습니다. 유럽도 중요한 역할을 하고 있으며, 특히 독일과 영국에서는 유럽 신경내분비종양학회(ENETS)와 같은 구상이 연구자와 임상의의 협력을 촉진하고 치료 프로토콜과 치료 접근성을 강화하는 데 기여하고 있습니다. 아시아태평양에서는 중국과 인도와 같은 신흥 시장에서 신경내분비종양에 대한 인식과 진단율이 높아지면서 의료 서비스 프로바이더들이 치료 옵션을 확대할 수 있도록 장려하고 있습니다. 또한 일본 신경내분비종양학회와 같은 구상은 신경내분비종양에 대한 이해와 관리를 개선하기 위한 노력을 기울이고 있으며, 이는 시장의 존재감을 높이는 데 일조하고 있습니다. 결과적으로, 이러한 지역별 인사이트는 치료의 발전과 연구 집중도가 다른 역동적인 상황을 보여주고 있습니다.

신경내분비종양치료제 시장 - 경쟁 구도 :

신경내분비종양(NET) 치료제 시장 경쟁 구도는 제약 대기업과 전문 생명공학 기업 등 다양한 기업이 참여하고 있으며, 노바티스(Novartis)와 입센(Ipsen)과 같은 선도 기업이 선두를 달리고 있으며, 산도스타틴(Sandostatin)과 소마툴린(Somatuline)과 같은 치료제가 증상 치료 및 종양 제어 시장을 장악하고 있습니다. 노바티스는 2023년 산도스타틴의 매출이 20억 달러 이상에 달할 것으로 예상하고 있으며, 노바티스의 자회사 Advanced Accelerator Applications와 Clovis Oncology와 같은 신흥 업체도 있습니다. Oncology와 같은 신흥 업체들은 방사성 리간드 치료 및 표적 치료와 같은 혁신적인 치료법을 개발하여 임상에서 인기를 얻고 있습니다. 바이엘과 화이자와 같은 기업이 인수 및 합병을 통해 제품 포트폴리오를 강화하려는 가운데, 공동 연구 및 전략적 제휴도 활발히 이루어지고 있으며, 특히 바이엘은 표적 방사성 핵종 치료용 루테튬 루테튬 루테튬 177의 권리를 획득한 바 있습니다. 또한 새로운 치료법을 찾기 위한 수많은 임상시험이 진행되고 있으며, 이는 NET 치료에서 환자 결과를 개선하기 위한 활발한 경쟁 환경을 반영하는 것으로, 연구개발에 대한 집중도가 여전히 높습니다.

서론
북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 이탈리아
- 영국
- 프랑스
- 러시아
- 네덜란드
- 스웨덴
- 폴란드
- 기타
아시아태평양(APAC)
- 개요
- 아시아태평양의 주요 제조업체
- 인도
- 중국
- 일본
- 한국
- 호주
- 태국
- 인도네시아
- 필리핀
- 기타
라틴아메리카
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 터키
- 알제리
- 이집트
- 기타

제12장 주요 벤더 분석 - 신경내분비종양 치료 업계

경쟁 대시보드
기업 개요
- Novartis AG
- Pfizer Inc.
- Ipsen SA
- Advanced Accelerator Applications SA
- Merck &Co., Inc.
- AstraZeneca PLC
- Roche Holding AG
- Bristol-Myers Squibb Company
- Bayer AG
- GlaxoSmithKline plc
- Eli Lilly and Company
- Sanofi SA
- Boehringer Ingelheim GmbH
- Teva Pharmaceutical Industries Ltd.
- Hutchison China MediTech Limited(Hutchmed)
- Lexicon Pharmaceuticals, Inc.
- Others

제13장 애널리스트의 전방위 전망

KSA 24.11.14

REPORT HIGHLIGHT

Neuroendocrine Tumor Treatment Market size was valued at USD 2,510.21 Million in 2023, expanding at a CAGR of 9.10% from 2024 to 2032.

The Neuroendocrine Tumor Treatment Market focuses on therapies designed to manage neuroendocrine tumors (NETs), which originate from neuroendocrine cells and can occur in various organs. With an increasing global incidence of NETs-affecting approximately 6.98 cases per 100,000 people-the demand for effective treatment options is on the rise. Rising awareness about NETs, advancements in targeted therapies, and the growing number of clinical trials contribute significantly to market growth. However, high treatment costs and a lack of knowledge among healthcare professionals can hinder market expansion. Opportunities lie in the development of novel therapeutics and combination therapies, along with the potential for personalized medicine, which could enhance treatment efficacy. As healthcare systems evolve, the integration of advanced diagnostic techniques, such as PET scans and molecular imaging, is anticipated to improve patient outcomes and drive further growth in the market.

Neuroendocrine Tumor Treatment Market- Market Dynamics

Growing Number of Clinical Trials Accelerates Innovation in the Neuroendocrine Tumor Treatment Market

The growing number of clinical trials is significantly accelerating innovation in the neuroendocrine tumor (NET) treatment market, reflecting an increasing focus on developing targeted therapies. For instance, in 2021, the National Institutes of Health (NIH) reported over 350 active clinical trials specifically for NETs, highlighting the urgency to explore new treatment avenues. Pharmaceutical companies such as Novartis and Ipsen have invested heavily in clinical research to evaluate novel agents, including somatostatin analogs and peptide receptor radionuclide therapy (PRRT). Furthermore, initiatives like the European Neuroendocrine Tumor Society (ENETS) have been instrumental in promoting collaborative research efforts, enabling faster advancements in treatment protocols. As a result, these efforts are anticipated to yield promising new therapies that enhance patient outcomes and quality of life for those diagnosed with neuroendocrine tumors.

Neuroendocrine Tumor Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 9.10% over the forecast period (2024-2032)

Based on Therapy Type segmentation, Somatostatin Analog Therapy was predicted to show maximum market share in the year 2023

Based on Drug Class segmentation, Somatostatin Analogs was the leading type in 2023

Based on Tumor Type segmentation, Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) were the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Neuroendocrine Tumor Treatment Market- Segmentation Analysis:

The Global Neuroendocrine Tumor Treatment Market is segmented on the basis of Therapy Type, Drug Class, Tumor Type, End-User, and Region.

The market is divided into four categories based on Therapy Type: Somatostatin Analog Therapy, Peptide Receptor Radionuclide Therapy (PRRT), Targeted Therapy, and Chemotherapy. Somatostatin Analog Therapy leads due to its established efficacy in symptom management. Following closely is Peptide Receptor Radionuclide Therapy (PRRT), gaining traction for targeted treatment. Targeted Therapy and Chemotherapy are also important, albeit with lower priority.

The market is divided into four categories based on Drug Class: Somatostatin Analogs, Tyrosine Kinase Inhibitors, mTOR Inhibitors, and Alkylating Agents. Somatostatin Analogs hold the highest priority due to their effectiveness in managing symptoms and tumor growth. Tyrosine Kinase Inhibitors follow, offering targeted action. mTOR Inhibitors and Alkylating Agents are also significant but with lower priority.

Neuroendocrine Tumor Treatment Market- Geographical Insights

The neuroendocrine tumor (NET) treatment market exhibits significant geographical variations in prevalence, treatment options, and research activities. North America stands out as the leading region, driven by advanced healthcare infrastructure and substantial investment in oncology research, with the U.S. reporting approximately 12,000 new NET cases annually according to the American Cancer Society. Europe also plays a crucial role, particularly in countries like Germany and the UK, where initiatives like the European Neuroendocrine Tumor Society (ENETS) foster collaboration among researchers and clinicians to enhance treatment protocols and access to therapies. In Asia-Pacific, emerging markets such as China and India are witnessing increasing awareness and diagnosis rates of neuroendocrine tumors, prompting healthcare providers to expand treatment options. Additionally, initiatives like the Japanese Society of Neuroendocrine Tumors are working to improve the understanding and management of NETs, thereby contributing to a growing market presence. As a result, these geographical insights indicate a dynamic landscape with varying levels of treatment advancements and research emphasis.

Neuroendocrine Tumor Treatment Market- Competitive Landscape:

The competitive landscape of the neuroendocrine tumor (NET) treatment market is characterized by a diverse array of players, including pharmaceutical giants and specialized biotech companies. Leading organizations such as Novartis and Ipsen are at the forefront, with their drugs, including Sandostatin and Somatuline, dominating the market for symptomatic treatment and tumor control. In 2023, Novartis reported over $2 billion in sales for Sandostatin, underscoring its significant market share. Emerging players like Advanced Accelerator Applications (a Novartis subsidiary) and Clovis Oncology are making strides with innovative therapies, including radioligand treatments and targeted therapies, which are gaining traction in clinical settings. Collaborations and strategic partnerships are also prevalent, as companies like Bayer and Pfizer seek to enhance their product portfolios through acquisitions and mergers, notably Bayer's acquisition of the rights to Lutetium Lu 177 for targeted radionuclide therapy. Furthermore, the focus on research and development remains high, with numerous clinical trials exploring novel treatment modalities, reflecting a vibrant and competitive environment aimed at improving patient outcomes in NET treatment.

Recent Developments:

In January 2024, the FDA's approval of Lu 177-dotatate (Lutathera) as an initial treatment for advanced neuroendocrine tumors, showed significant improvements in progression-free survival and tumor shrinkage when combined with octreotide, enhancing therapeutic options for patients.

In March 2024, the FDA granted breakthrough therapy designation to AlphaMedix (212Pb-DOTAMTATE) for treating advanced gastroenteropancreatic neuroendocrine tumors. This marks a significant advancement as it is the first targeted alpha therapy to receive this status, expediting its development.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Novartis AG
Pfizer Inc.
Ipsen S.A.
Advanced Accelerator Applications S.A.
Merck & Co., Inc.
AstraZeneca PLC
Roche Holding AG
Bristol-Myers Squibb Company
Bayer AG
GlaxoSmithKline plc
Eli Lilly and Company
Sanofi S.A.
Boehringer Ingelheim GmbH
Teva Pharmaceutical Industries Ltd.
Hutchison China MediTech Limited (Hutchmed)
Lexicon Pharmaceuticals, Inc.
Others

GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2019 - 2032

Somatostatin Analog Therapy
Peptide Receptor Radionuclide Therapy (PRRT)
Targeted Therapy
Chemotherapy

GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

Somatostatin Analogs
Tyrosine Kinase Inhibitors
mTOR Inhibitors
Alkylating Agents

GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET, BY TUMOR TYPE- MARKET ANALYSIS, 2019 - 2032

Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Lung Neuroendocrine Tumors
Others

GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

Hospitals
Cancer Specialty Clinics
Research Institutes

GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Neuroendocrine Tumor Treatment Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Neuroendocrine Tumor Treatment Market Snippet by Therapy Type
- 2.1.2. Neuroendocrine Tumor Treatment Market Snippet by Drug Class
- 2.1.3. Neuroendocrine Tumor Treatment Market Snippet by Tumor Type
- 2.1.4. Neuroendocrine Tumor Treatment Market Snippet by End-User
- 2.1.5. Neuroendocrine Tumor Treatment Market Snippet by Country
- 2.1.6. Neuroendocrine Tumor Treatment Market Snippet by Region
2.2. Competitive Insights

3. Neuroendocrine Tumor Treatment Key Market Trends

3.1. Neuroendocrine Tumor Treatment Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Neuroendocrine Tumor Treatment Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Neuroendocrine Tumor Treatment Market Opportunities
3.4. Neuroendocrine Tumor Treatment Market Future Trends

4. Neuroendocrine Tumor Treatment Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Neuroendocrine Tumor Treatment Market: COVID-19 Impact Analysis

5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments

6. Neuroendocrine Tumor Treatment Market Landscape

6.1. Neuroendocrine Tumor Treatment Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Neuroendocrine Tumor Treatment Market - By Therapy Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Therapy Type, 2023 & 2032 (%)
- 7.1.2. Somatostatin Analog Therapy
- 7.1.3. Peptide Receptor Radionuclide Therapy (PRRT)
- 7.1.4. Targeted Therapy
- 7.1.5. Chemotherapy

8. Neuroendocrine Tumor Treatment Market - By Drug Class

8.1. Overview
- 8.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
- 8.1.2. Somatostatin Analogs
- 8.1.3. Tyrosine Kinase Inhibitors
- 8.1.4. mTOR Inhibitors
- 8.1.5. Alkylating Agents

9. Neuroendocrine Tumor Treatment Market - By Tumor Type

9.1. Overview
- 9.1.1. Segment Share Analysis, By Tumor Type, 2023 & 2032 (%)
- 9.1.2. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
- 9.1.3. Lung Neuroendocrine Tumors
- 9.1.4. Others

10. Neuroendocrine Tumor Treatment Market - By End-User

10.1. Overview
- 10.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
- 10.1.2. Hospitals
- 10.1.3. Cancer Specialty Clinics
- 10.1.4. Research Institutes

11. Neuroendocrine Tumor Treatment Market- By Geography

11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
11.2. North America
- 11.2.1. Overview
- 11.2.2. Neuroendocrine Tumor Treatment Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.2.8. U.S.
  - 11.2.8.1. Overview
  - 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.8.3. U.S. Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.2.8.4. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.2.8.5. U.S. Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
  - 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.2.9. Canada
  - 11.2.9.1. Overview
  - 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.9.3. Canada Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.2.9.4. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.2.9.5. Canada Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
  - 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3. Europe
- 11.3.1. Overview
- 11.3.2. Neuroendocrine Tumor Treatment Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.8. Germany
  - 11.3.8.1. Overview
  - 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.8.3. Germany Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.8.4. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.8.5. Germany Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
  - 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.9. Italy
  - 11.3.9.1. Overview
  - 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.9.3. Italy Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.9.4. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.9.5. Italy Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
  - 11.3.9.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.10. United Kingdom
  - 11.3.10.1. Overview
  - 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.10.3. United Kingdom Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.10.4. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.10.5. United Kingdom Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
  - 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.11. France
  - 11.3.11.1. Overview
  - 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.11.3. France Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.11.4. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.11.5. France Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
  - 11.3.11.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.12. Russia
  - 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.12.2. Russia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.12.3. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.12.4. Russia Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
  - 11.3.12.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.13. Netherlands
  - 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.13.2. Netherlands Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.13.3. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.13.4. Netherlands Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
  - 11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.14. Sweden
  - 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.14.2. Sweden Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.14.3. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.14.4. Sweden Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
  - 11.3.14.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.15. Poland
  - 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.15.2. Poland Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.15.3. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.15.4. Poland Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
  - 11.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.16. Rest of Europe
  - 11.3.16.1. Overview
  - 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.16.3. Rest of the Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.16.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.16.5. Rest of the Europe Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
  - 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. Neuroendocrine Tumor Treatment Key Manufacturers in Asia Pacific
- 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.4.4. Asia Pacific Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 11.4.5. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.4.6. Asia Pacific Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
- 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.8. India
  - 11.4.8.1. Overview
  - 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.8.3. India Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.8.4. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.8.5. India Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
  - 11.4.8.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.9. China
  - 11.4.9.1. Overview
  - 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.9.3. China Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.9.4. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.9.5. China Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
  - 11.4.9.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.10. Japan
  - 11.4.10.1. Overview
  - 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.10.3. Japan Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.10.4. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.10.5. Japan Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
  - 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.11. South Korea
  - 11.4.11.1. Overview
  - 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.11.3. South Korea Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.11.4. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.11.5. South Korea Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
  - 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.12. Australia
  - 11.4.12.1. Overview
  - 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.12.3. Australia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.12.4. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.12.5. Australia Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
  - 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.13. Thailand
  - 11.4.13.1. Overview
  - 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.13.3. Thailand Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.13.4. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.13.5. Thailand Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
  - 11.4.13.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.14. Indonesia
  - 11.4.14.1. Overview
  - 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.14.3. Indonesia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.14.4. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.14.5. Indonesia Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
  - 11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.15. Philippines
  - 11.4.15.1. Overview
  - 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.15.3. Philippines Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.15.4. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.15.5. Philippines Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
  - 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.16. Rest of APAC
  - 11.4.16.1. Overview
  - 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.16.3. Rest of APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.16.4. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.16.5. Rest of APAC Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
  - 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5. Latin America
- 11.5.1. Overview
- 11.5.2. Neuroendocrine Tumor Treatment Key Manufacturers in Latin America
- 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.5.4. Latin America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 11.5.5. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.5.6. Latin America Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
- 11.5.7. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.8. Brazil
  - 11.5.8.1. Overview
  - 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.8.3. Brazil Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.5.8.4. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.8.5. Brazil Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
  - 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.9. Mexico
  - 11.5.9.1. Overview
  - 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.9.3. Mexico Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.5.9.4. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.9.5. Mexico Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
  - 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.10. Argentina
  - 11.5.10.1. Overview
  - 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.10.3. Argentina Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.5.10.4. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.10.5. Argentina Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
  - 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.11. Colombia
  - 11.5.11.1. Overview
  - 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.11.3. Colombia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.5.11.4. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.11.5. Colombia Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
  - 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.12. Rest of LATAM
  - 11.5.12.1. Overview
  - 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.12.3. Rest of LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.5.12.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.12.5. Rest of LATAM Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
  - 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa
- 11.6.1. Overview
- 11.6.2. Neuroendocrine Tumor Treatment Key Manufacturers in Middle East and Africa
- 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.6.4. Middle East and Africa Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 11.6.5. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.6.6. Middle East and Africa Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
- 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.8. Saudi Arabia
  - 11.6.8.1. Overview
  - 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.8.3. Saudi Arabia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.8.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.8.5. Saudi Arabia Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
  - 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.9. United Arab Emirates
  - 11.6.9.1. Overview
  - 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.9.3. United Arab Emirates Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.9.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.9.5. United Arab Emirates Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
  - 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.10. Israel
  - 11.6.10.1. Overview
  - 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.10.3. Israel Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.10.4. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.10.5. Israel Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
  - 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.11. Turkey
  - 11.6.11.1. Overview
  - 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.11.3. Turkey Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.11.4. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.11.5. Turkey Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
  - 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.12. Algeria
  - 11.6.12.1. Overview
  - 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.12.3. Algeria Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.12.4. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.12.5. Algeria Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
  - 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.13. Egypt
  - 11.6.13.1. Overview
  - 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.13.3. Egypt Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.13.4. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.13.5. Egypt Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
  - 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.14. Rest of MEA
  - 11.6.14.1. Overview
  - 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.14.3. Rest of MEA Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.14.4. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.14.5. Rest of MEA Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
  - 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Neuroendocrine Tumor Treatment Industry

12.1. Competitive Dashboard
12.2. Company Profiles
- 12.2.1. Novartis AG
- 12.2.2. Pfizer Inc.
- 12.2.3. Ipsen S.A.
- 12.2.4. Advanced Accelerator Applications S.A.
- 12.2.5. Merck & Co., Inc.
- 12.2.6. AstraZeneca PLC
- 12.2.7. Roche Holding AG
- 12.2.8. Bristol-Myers Squibb Company
- 12.2.9. Bayer AG
- 12.2.10. GlaxoSmithKline plc
- 12.2.11. Eli Lilly and Company
- 12.2.12. Sanofi S.A.
- 12.2.13. Boehringer Ingelheim GmbH
- 12.2.14. Teva Pharmaceutical Industries Ltd.
- 12.2.15. Hutchison China MediTech Limited (Hutchmed)
- 12.2.16. Lexicon Pharmaceuticals, Inc.
- 12.2.17. Others

13. 360 Degree Analyst View

14. Appendix

14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us